Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like ADC Drops Goal of Accelerated Approval for Cami in Hodgkins November 9, 2022 EU Adds Rare Spinal Condition to J&J COVID-19 Side Effects November 11, 2021 IQVIA Reports Record Novel Drug Launches in 2021 February 10, 2022